Delivery Order SPE2DB22D1103-SPE2DB24FTPF1

Award Date 7/26/24
Potential Completion Date 7/29/24
Potential Value $4.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,558.53 firm fixed-price delivery order is for the supply of Telmisartan-HCTZ 80-12.5 mg tablets. The contract has an ultimate completion date of March 11, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,364.08 firm fixed-price delivery order is for the supply of Telmisartan 80 mg tablets. The contract has an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,390.59, is for the delivery of Telmisartan-HCTZ 40-12.5 mg tablets in units of 30. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,469.20, is for the delivery of Telmisartan-HCTZ 80-12.5 mg tablets. This is a Firm Fixed Price Delivery Order contract with a performance period through March 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,696.78 firm-fixed-price delivery order is for Telmisartan-HCTZ 40-12.5 mg tablets, with a performance period ending on February 25, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $7,517.54, is a Delivery Order contract for the supply of Telmisartan-HCTZ 80-25 mg tablets. The contract has an ultimate completion date of April 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The delivery order, valued at $6,285.77, is for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in bottles of 30 to support military healthcare programs. The contract has a firm fixed price and an ultimate completion date of November 12, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,792.95 Firm Fixed Price delivery order is for the supply of Telmisartan-Amlodipine 40-5 mg tablets. The contract has an ultimate completion date of November 13, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $4,039.24, is for the delivery of Telmisartan-HCTZ 80-25 mg tablets in 30-count units. The contract is a Firm Fixed Price Delivery Order with a period of performance running through February 28, 2025. There is no set-aside designation associated with this award. Amerisourcebergen holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,631.94, is a delivery order for the supply of Telmisartan-Amlodipine 40-5 mg tablets. The contract has an ultimate completion date of March 7, 2025 and is a firm fixed-price agreement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB24FTPF1
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $4,255.27, is for the delivery of Telmisartan-HCTZ 80-25 mg tablets. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of July 29, 2024.

AmerisourceBergen has an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/17/25, 10:05 AM